Leadership & Pay ·
Tango Therapeutics, Inc. announced that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026…
TNGXTango Therapeutics, Inc.
Tango Therapeutics, Inc. announced that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, resulting in her resignation from all officer and board positions. The separation agreement provides severance pay through December 31, 2026, COBRA premium reimbursement until the same date, acceleration of equity vesting for twelve months post-termination, an extended option exercise period, and a pro-rata annual incentive payment by March 15, 2027. The resignation was not due to disagreements regarding operations or policies. Tango Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted therapies for cancer.